Athersys, Inc. (NASDAQ:ATHX) jumped 27.78% up to $3.68 on heavy volume with 5,479,849 shares trading on news the company was issued two US patents protecting the intellectual rights to its non-embryonic multipotent stem cells, the applications of isolation and expansion, and related pharmaceutical compositions;  non-embryonic pluripotent stem cells, their isolation, expansion, and usage, respectively.  The new patents expand on Athersys’ existing portfolio of 14 patents with an additional120 global patent applications supporting its stem cell technology and MultiStem product platform.  Based in Cleveland, Ohio, Athersys, Inc is a biopharmaceutical company producing non-embryonic cell product candidates for the treatment of multiple diseases. Athersys also develops orally administered pharmaceuticals to treat central nervous system disorders, such as narcolepsy, excessive daytime sleepiness, and chronic fatigue associated with Parkinson’s disease and schizophrenia.  In late December the biotech company entered into an alliance with big Pharma, Pfizer, to develop Athersys’ stem cell technology, the announcement sent the stock soaring more than 400%.  The global stem cell market is currently valued at $4.5 billion and growing rapidly at a compound annual rate of 27.3%; the market is expected to be worth $15 billion by 2015.  Another driver for activity in the biopharmaceutical sector has been a recent upsurge in strategic mergers & acquisitions: a 2009 Ernst & Young report revealed merger & acquisition activity was worth $28.5 billion in deals in 2008 in the US alone. The report also explained that the biotech industry has been helped by President Barack Obama’s pronouncement that the US government should spend more than 3% of its GDP on scientific research and development. ATHX has broken through resistance and is trading above its 90 day moving average of $1.98.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

A.P. Pharma, Inc. (NASDAQ:APPA) gained 16.42% up to $1.56 on no news since the company reported regaining  compliance with the Nasdaq minimum bid rule in January.  The company also reported receiving a royalty payment of $2.5 million for rights to Retin-A Micro and Carac it sold to an affiliate of the Paul Capital Healthcare. Based in Redwood City, California, A.P. Pharma, Inc., is a pharmaceutical company developing pharmaceutical products applying its proprietary Biochronomer polymer-based drug delivery technology. Its lead product candidate is APF530, which completed pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting. The New Drug Application (NDA) for APF530 was submitted to the FDA in May 2009 and accepted for review in July 2009, at which time the FDA set a Prescription Drug User Fee Act (PDUFA) date of March 18, 2010.

Zagg Inc(NDA) (NASDAQ:ZAGG) rose 17.63% up to $2.87 on news the company has already begun accepting pre-orders for invisibleSHIELD for the Apple iPad. Headquartered in Salt Lake City, Utah, ZAGG Incorporated designs, manufactures, and distributes protective coverings, audio accessories, and power solutions for consumer electronic and hand-held devices, under the invisibleSHIELD and ZAGGaudio brand names, primarily in the US and Europe.  The company’s proprietary protective coverings are outfitted for iPhones, Blackberrys, iPods, and many other electronic devices.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

La Jolla Pharmaceutical Company (NASDAQ:LJPC) advanced 23.36% up to $0.1360 on no news; however the biopharmaceutical company announced this week it expects that NASDAQ will take action to begin proceedings to delist the company’s common stock. Based in San Diego, California La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery and development of small molecule therapy for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders and acute and chronic inflammatory disorders such as Lupus.

CombinatoRx, Incorporated (NASDAQ:CRXX) rose 14.02% up to $1.22 on no news since the company announced changes to its senior management team following its merger with Neuromed.  The company expects news on February 22nd from the FDA regarding a review of the New Drug Application for Neuromed’s drug candidate Exalgo for pain management.  CRXX is surging on heavy volume and trading above its 200 day moving average of $1.05.  Based in Cambridge, Massachusetts, CombinatoRx, Inc., is a biopharmaceutical company which discovers, develops, and out-licenses combination pharmaceuticals created by blending drugs to treat various diseases, cancer, metabolic diseases, inherited diseases, and other medical conditions.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Antigenics, Inc. (NASDAQ:AGEN) rose 40.40% up to $1.09 with 7,445,439 shares moving on no news in early afternoon trading.  Headquartered in Lexington, Massachusetts the biotechnology company develops cancer vaccines and other treatments for cancer and infectious diseases.

Pharmacyclics, Inc. (NASDAQ:PCYC) gained 19.66% up to $4.20, to a 52 week high on no news; and up 635% since last February when the stock was trading at a low of $0.57. Headquartered in Sunnyvale, California, Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company which develops and commercializes small-molecule drugs for the treatment of auto-immune diseases and cancer. The company’s products in clinical development include HDAC Inhibitor for advanced solid tumours, recurrent lymphomas, and sarcoma; Btk Inhibitors for the treatment of lymphoma and auto-immune diseases; Factor VIIa Inhibitor for pancreatic cancer; and Motexafin Gadolinium for brain cancer.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Peregrine Diamonds Ltd. (TSX: PGD), $2.25, +0.13, 6.13%, is the heaviest traded company on the TSX this morning, making gains of over 6% and trading in the range of 2.38 to 2.13.  This past September the stock hit a 52 week-high of 4.65.  Peregrine Diamonds is a diamond exploration and development company in Canada.  Since 2007 it has discovered two new diamond areas in Canada.  The last company announcement was on the appointment of Mike Westerlund to the position of Vice President, Investor Relations and Corporate Communications.

Victoria Gold Corp. (TSX: VIT), $0.84, +0.07, 9.09%, reached a new 52 week-high today of 0.90, and is currently trading slightly above the day’s low of 0.82.  Victoria Gold is a growth gold company focusing on exploration, development and acquisitions.  VIT announced today its assay results from diamond drill hole BH-3 at the Santa Fe gold exploration project in Nevada. Chad Williams, the company’s President, Director and CEO reported “Similar to drill hole BH-2’s interval of 309 m grading 2.25 g/t reported on October 22, 2009, BH-3 returned a very wide interval of gold mineralization; importantly, BH-3 also contained a higher-grade mineralized block having a minimum of 11.3 m grading 11.46 g/t which Victoria views as very encouraging.”

Converted Organics Inc. (NASDAQ: COIN), $1.24, +0.338, 37.47%, is making gains today trading near the day’s high of 1.25, touching down on a low of 0.92.  The company is focused on producing organic soil amendment and fertilizer products through food waste recycling.  Converted Organics reported today that further to the orders it received from Walmart, it now has also received orders from Sam’s Club of Puerto Rico and the Amigos supermarket chain of Puerto Rico. Both Sam’s Club and Amigos are affiliates of Walmart.

Uluru Inc. (AMEX: ULU), $0.246, +0.006, 2.29%, is steadily trading today in the range of 0.22 and 0.26 slightly above its average volume on no news.  Last major company announcement was on the approval by McKesson Medical-Surgical, Inc., a major pharmaceutical distributor, to have Uluru Inc. be one of its suppliers and has placed its first significant order for Altrazeal™. Uluru Inc. is a pharmaceutical company focused on the development wound management and oral care products.

About Picksthatmove.com

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies. PicksThatMove.com is not a registered investment advisor or broker-dealer. PicksThatMove.com’s affiliates, offices, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  Please follow us on Twitter and Facebook for further investment updates.  We recommend you do your own Due Diligence before investing in any of the stocks mentioned above.

Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  Please visit us at PicksThatMove.com to view more of our profiled stocks.

Keep Semiconductor Technology On Your Radar: INTT

The hot stock information of the day includes:   INTT, ANSV

inTEST Corporation (NASDAQ:INTT) advanced 12.75% to close at $0.620, after reaching a high today of  $0.75 with volume doubling on no news. Headquartered in Cherry Hill, New Jersey, inTEST Corporation designs, manufactures, and markets mechanical, thermal, and electrical products. End users of the products are semiconductor manufacturers for testing integrated circuits or semiconductors primarily for automotive, aerospace, computer, consumer products, and telecommunications industries. InTEST Corporation’s stock has appreciated 210% since August.

Anesiva Inc. (NASDAQ:ANSV) jumped 20.00% to close at $0.180 on no news. Headquartered in South San Francisco, California, Anesiva Inc is a biopharmaceutical company which develops and commercializes therapeutic treatments for pain management.   The company’s lead drug candidate Adlea, has completed multiple Phase II and Phase III trials for post-surgical, musculoskeletal, osteoarthritis and neuropathic pain.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  Please visit us at PicksThatMove.com to view more of our profiled stocks.

Mixed Signals In Healthcare: ETRM, LJPC Swing Gains

The hot stock information of the day includes:  ETRM, LJPC

EnteroMedics Inc. (NASDAQ:ETRM) jumped 21.25% up to $0.631 at midday on no news; however following dismal Q3 results last Friday which reported a net loss of $12.0 million, or $0.40 per share and disappointing preliminary findings in a key clinical trial assessing its anti-obesity device Maestro System, the company announced it will sack 40% of its workforce  - a total of 33 people will be terminated  by November 15, 2009.  Headquartered in St. Paul, Minnesota EnteroMedics Inc is a development stage medical device company designing, testing and developing devices that use neuron-blocking technology to cure obesity and treat other gastrointestinal disorders.  The company’s lead proprietary technology is designed to intermittently block a specific nerve using electrical impulses.  The Maestro System applies a limit to the expansion of the stomach to control hunger sensations between meals and produce a feeling of early and prolonged fullness.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) soared 41.48% up to $0.0880 on no news; however the embattled biopharmaceutical company will hold a special stock holders meeting on Friday, October 30th to vote on a Plan of Complete Liquidation and Dissolution. If the proposal is approved, the company would expect to dissolve shortly after the stockholders’ meeting and begin liquidation to satisfy remaining creditor obligations and distribute any remaining cash once the dissolution is complete.  As of August 31, 2009, La Jolla Pharmaceutical had cash, net of liabilities and obligations of roughly $4.4 million.  After projected operating and shut down costs, the company projects that there will be between $0.028 and $0.045 per share available for distribution to holders of the approximately 66 million shares of common stock issued and outstanding stock.  While the La Jolla Pharmaceutical is seeking stockholder approval for the dissolution, the company expects to maintain its listing on the NASDAQ; however if the dissolution is not completed by November 6th, they expect that NASDAQ will take action at that time to commence proceedings to delist the company’s common stock.  Based in San Diego, California, La Jolla Pharmaceutical is a biopharmaceutical company focused on the discovery and development of small molecule therapy for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders and acute and chronic inflammatory disorders such as Lupus.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  Please visit us at PicksThatMove.com to view more of our profiled stocks.

DUSA And HH Lead Biopharmaceuticals And Healthcare Movers

The hot stock information of the day includes:  DUSA, RNN, HH

DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA) jumped 27.07% up to $1.69 on no news this morning.  Based in Wilmington, Massachusetts, DUSA Pharmaceuticals, Inc., is a dermatology pharmaceutical company, which develops and markets dermatological treatments for the treatment of pre-cancerous skin lesions known as Actinic Keratoses, moderate inflammatory acne vulgaris and general dermatological conditions.  The company’s proprietary product line includes Levulan and  KerastickBLU-U light therapies and ClindaReach, a medicated swab device which allows for the application of topical clindamycin phosphate solution to hard to reach places on the skin’s surface. 

Rexahn Pharmaceuticals, Inc. (AMEX:RNN) rose 20.57% up to $0.940 on news the company’s  drug candidate Serdaxin showed positive results in a Phase IIa clinical study which has assessed the product’s safety and efficacy for the treatment of severe depression. Based in Rockville, Maryland, Rexahn Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company which discovers, develops, and commercializes treatments for cancer, central nervous system disorders, sexual dysfunction in the US. The company currently has three drug candidates in Phase II clinical trials which include Serdaxin for the treatment of depression, Archexin for the treatment of renal cell carcinoma and pancreatic cancer; and Zoraxel for the treatment of sexual dysfunction.

Hooper Holmes, Inc. (AMEX:HH) advanced 28.56% up to $0.900 on no official news.  Headquartered in Basking Ridge, New Jersey, Hooper Holmes, Inc., together with its subsidiaries, provides outsourced risk assessment services to the life and health insurance industry in the US and provides paramedical and medical examinations of applicants for insurance, primarily life insurance, through a network of paramedical examiners, including phlebotomists, registered nurses, licensed practitioner nurses, emergency medical technicians, and other medically trained professionals.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  Please visit us at PicksThatMove.com to view more of our profiled stocks.

Flu Season Officially Hits And BioPharmaceuticals Surge On News The First Nasal Vaccines Have Already Been Delivered

The hot stock information of the day includes:  HEB, ENMD, VSGN

Hemispherx BioPharma, Inc (AMEX:HEB) traded up 12.72% to close at $1.95 on news data for the company’s experimental immunotherapeutic, Ampligen, will be reviewed at the “Mucosal Immunity” session of the Japan-France Vaccine and Infectious Diseases Workshop in Osaka, on Saturday October 10th. The first nasal mist swine flu vaccines have been distributed this week in the US; and vaccine needles scheduled to be distributed later in October. Founded in 1990 and headquartered in Philadelphia, Pennsylvania, Hemispherx BioPharma Inc., is a biopharmaceutical company which clinically develops, manufactures, markets, and distributes new drug therapies for the treatment of viral and immune based chronic disorders.

EntreMed, Inc. (NASDAQ:ENMD) surged 63.16% to close at $0.930 with 3,972,240 shares traded on no news. Headquartered in Rockville, Maryland, EntreMed is a clinical-stage pharmaceutical company which develops drug candidates chiefly for the treatment of cancer and inflammation.  The company currently has four drug candidates in clinical trials, including ENMD-2076, MKC-1, ENMD-1198, and Panzem for the treatment of various advanced cancers.

Vasogen Inc. (USA) (NASDAQ:VSGN) rose 12.24% to close at $0.310 on no news; however the company will  hold a shareholder vote this month to approve and  finalize a merger with IntelliPharmaCeutics International Ltd, and also to approve an arrangement agreement with Cervus to provide gross proceeds to the company of approximately $7.5 million.  Headquartered in Mississauga, Ontario, VasoGene is a clinical-stage company which develops and commercializes innovative therapeutics based on the understanding of vascular biology.  

 To be kept up to date on all of our hot stock information join us at Picks That Move.

 About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock.

Calgary, Alberta - PicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  Please visit us at PicksThatMove.com to view more of our profiled stocks.

Positive Clinical Data For Weight Loss Diet Sends Stock Soaring:  Interleukin Genetics, Inc

The hot stock information of the day includes:  ILI, KERX

Interleukin Genetics, Inc (Public, AMEX:ILI) soared 272.34% up to $1.75 on news the company’s genotype-matched diet showed excellent weight loss results in clinical tests.  According to Markets and Markets the global weight management market is estimated at US$363 billion in 2009.  Headquartered in Waltham, Massachusetts Interleukin Genetics develops and commercializes personally tailored health care products in the US and internationally.   Interleukin Genetics has research collaborations with the University of Sheffield, Tufts University, New York University, Harvard University, the Mayo Clinic, California Pacific Medical Center, Boston University, the University of Arkansas, Tongji Medical College, University of North Carolina, and Yonsei University.

Keryx Biopharmaceuticals (NASDAQ:KERX) climbed 21.61% up to $2.87  on news the company’s drug candidate, Zerenex, yielded positive results, was tolerated and safe in a mid-stage trials for long term use in patients with end-stage kidney disease.  The company also benefitted from analysts at Brean Murray raising the company’s target price of $3 to $5 and maintaining a ‘Buy’ rating today.  Based in New York, New York, Keryx Biopharmaceuticals develops and commercializes drugs and treatments of life-threatening ailments associated with renal diseases and cancer.  The company’s stock has appreciated 2277.39% since the end of March.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock.